Latest Ratios: P/E Ratio -42.2x · EV/EBITDA N/A · ROE -141.7%. (2023–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Market Cap | $289M | $54M | — | — |
| Enterprise Value | $284M | $49M | — | — |
| P/E Ratio → | -42.22 | — | — | — |
| P/S Ratio | — | — | — | — |
| P/B Ratio | 28.47 | 11.55 | — | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| EV / Revenue | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Profit Margin | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ROE | -141.7% | -141.7% | — | -2672.6% |
| ROA | -45.0% | -45.0% | -87.1% | -113.8% |
| ROIC | — | — | — | — |
| ROCE | -156.2% | -156.2% | -125.5% | -151.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | — | 0.29 |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | -1.07 | — | -13.48 |
| Net Debt / EBITDA | — | — | — | — |
| Debt / FCF | — | — | — | — |
| Interest Coverage | — | — | — | — |
Net cash position: cash ($5M) exceeds total debt ($80376)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Current Ratio | 0.87 | 0.87 | 1.55 | 2.45 |
| Quick Ratio | 0.87 | 0.87 | 1.55 | 2.45 |
| Cash Ratio | 0.85 | 0.85 | 1.23 | 2.41 |
| Asset Turnover | — | — | — | — |
| Inventory Turnover | — | — | — | — |
| Days Sales Outstanding | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Earnings Yield | — | — | — | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $14M | $13M | $13M |
Pre-revenue liquidity exhaustion
According to current market data, TTRX trades at a price-to-book ratio of 20.32, which, as reported in financial statements, reflects a significant speculative premium that investors are assigning to the company's proprietary delivery platform rather than any tangible earnings or revenue-generating assets currently on the balance sheet.
The negative TTM P/E of -30.13 confirms that the market is pricing the firm as a high-risk option on future clinical success rather than a traditional operating entity. This valuation level appears detached from fundamental performance, suggesting that any delay in regulatory milestones could lead to a rapid compression of the current market capitalization.
Based on reported figures, the company's ROIC of -3.1% in 2026Q1 highlights a persistent inability to generate positive returns on invested capital, a trend that is typical for pre-commercial biotech firms where heavy R&D spending consistently outpaces the development of any viable, revenue-generating commercial products.
The negative ROE of -18.0% further underscores the destruction of shareholder value as the firm burns through its limited cash reserves to fund clinical validation. Investors should monitor whether management can pivot toward a more capital-efficient licensing model, as the current trajectory suggests that capital is being consumed without a corresponding increase in the underlying value of the firm's IP.
As indicated by the company's financial records, the days payable outstanding reached 16,330 in 2026Q1, a figure that suggests extreme reliance on extended supplier credit terms to manage liquidity in the absence of any meaningful cash inflows from core operations or product sales.
This reliance on stretched payables indicates that the company is effectively using its vendors to finance its ongoing research activities. Such a strategy is inherently fragile and may indicate that the firm lacks the necessary cash flow to meet its obligations in a timely manner without further dilutive equity or debt financing.
Based on recent quarterly filings, the current ratio of 2.23 in 2026Q1 provides a superficial appearance of stability, yet this metric masks the reality that the firm's liquidity is entirely dependent on external capital injections rather than internal cash generation from its core business activities.
The rapid shift in the debt-to-equity ratio from 0.02 to 0.98 over two quarters suggests that the company is exhausting its traditional liquidity buffers and turning to debt to sustain operations. This transition warrants close monitoring, as the lack of recurring revenue makes the current debt service obligations a significant risk to the company's long-term solvency.
As reported in financial statements, the price-to-book ratio of 20.32 is a commonly misapplied metric for TTRX because it fails to account for the fact that the company's primary assets are intangible intellectual property rather than physical infrastructure or tangible book value.
Investors should instead focus on the cash-to-burn ratio or the progress of clinical milestones, as these provide a more accurate reflection of the company's survival prospects. Relying on book value in a pre-revenue biotech context obscures the reality that the firm's value is tied to regulatory outcomes that are not captured on the balance sheet.
Includes 30+ ratios · 3 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TTRX stock.
Turn Therapeutics Inc.'s current P/E ratio is -42.2x. This places it at the 50th percentile of its historical range.
Turn Therapeutics Inc.'s return on equity (ROE) is -141.7%. The historical average is -141.7%.
Based on historical data, Turn Therapeutics Inc. is trading at a P/E of -42.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.